Abstract
This study aimed to analyze the clinical significance of serum ferritin, procalcitonin (PCT), and C-reactive protein (CRP) in patients with hemorrhagic fever with renal syndrome (HFRS). The demographical, clinical, and laboratory data of 373 patients with HFRS in northeastern China were retrospectively analyzed. The levels of serum ferritin and PCT in severe patients (n = 108) were significantly higher than those in mild patients (n = 265, p < 0.001) and associated with HFRS severity. The area under the receiver operating characteristic curve (AUC) values of serum ferritin and PCT for predicting the severity of HFRS were 0.732 (95% CI 0.678–0.786, p < 0.001) and 0.824 (95% CI 0.773–0.875, p < 0.001), respectively, showing sensitivity and specificity of 0.75 and 0.88 for serum ferritin, and 0.76 and 0.60 for PCT. The CRP level in HFRS with bacterial co-infection (n = 115) was higher than that without bacterial co-infection (n = 258, p < 0.001). The AUC value of CRP for predicting bacterial co-infection was 0.588 (95% CI 0.525–0.652, p < 0.001), showing sensitivity and specificity of 0.43 and 0.76, respectively. The serum ferritin level in non-survivors (n = 14) was significantly higher than in survivors (n = 359, p < 0.001). The AUC value of serum ferritin for predicting mortality was 0.853 (95% CI 0.774–0.933, p < 0.001), showing sensitivity and specificity of 0.933 and 0.739. Serum ferritin and PCT have a robust association with HFRS severity and mortality, which may be promising predictors, and CRP is an effective biomarker to assess bacterial co-infection in HFRS.
Introduction
Hemorrhagic fever with renal syndrome (HFRS) is caused by Hantaviruses of the genus Orthohantavirus in the family Hantaviridae and is characterized by acute kidney injury, increased vascular permeability, and coagulation abnormalities. HFRS is an important rodent-associated zoonosis endemic in eastern Asia, especially in China, accounting for ∼90% of the cases globally (Jonsson et al., 2010). Hantaan virus and Seoul virus are the major etiologies of HFRS in China that cause severe and mild forms of HFRS, respectively (Zhang et al., 2010). Although effective treatment and vaccination have greatly reduced the impact of HFRS in the past few decades in China, the number of infected patients still remains at a relatively high level, with ∼10,000 cases reported annually. Clinical parameters are necessary for improving the management of patients with HFRS, which may be used as clinical references for severity assessment and prognosis prediction (Du et al., 2014; Zhang et al., 2015).
Cytokine storm of excessive immune response plays a central role in the pathogenesis of HFRS, which can damage the vascular endothelial cell and accelerate platelet activation, leading to multi-organ dysfunction or failure (Wang et al., 2012). The pathophysiology of organ damage that occurs with hantavirus infection also motivates the increase in biomarkers, including ferritin, CRP, and PCT. Ferritin has been identified as an important molecule in the host immune system that can reflect the cellular defense against inflammatory response (Valero et al., 2019). Studies also have confirmed ferritin as a potential biomarker in the diagnosis of viral and bacterial infection, as well as macrophage-activation syndrome and hemophagocytic lymphohistiocytosis (Barut et al., 2010; Kyriazopoulou et al., 2017; Franco-Martinez et al., 2021; Zhou J. et al., 2021). Patients with HFRS appear to have a higher level of serum ferritin and PCT (Tjendra et al., 2020). Procalcitonin (PCT) is a precursor of calcitonin hormone secreted by different cells under inflammatory stimulation, which is increased and associated with disease severity, secondary bacterial infection, and mortality in patients with HFRS (Fan X. et al., 2018). C-reactive protein (CRP) is a sensitive biomarker of viral infection and inflammation (Shin et al., 2018). CRP and PCT can be used to evaluate disease severity and predict outcomes in patients with COVID-19 (Liu et al., 2020; Pan et al., 2020; Zhang et al., 2020, 2021; Zhou Y.Z. et al., 2021). In this study, we aimed to analyze the clinical significance of serum ferritin, procalcitonin (PCT), and C-reactive protein (CRP) in patients with HFRS.
Materials and Methods
Study Design
We collected the demographical, laboratory, and clinical data of patients with HFRS who were admitted to The First Hospital of Jilin University during 2018–2019. Patients who were hantavirus (HV) serological IgM positive, had typical clinical manifestations of febrile, hemorrhage, renal injury, and travel history to HV epidemiology areas were diagnosed with HFRS and included in this study. Exclusion criteria included other infections similar to HFRS, hantaviruses IgM negative, or acute kidney injury due to other diseases (e.g., dehydration, hemorrhagic shock, glomerulonephritis, and acute intoxication).
To investigate the change of serum ferritin, PCT, and CRP associated with severity, bacterial co-infection, and death due to HFRS, we divided the patients into two groups according to the classification criteria (Escutenaire and Pastoret, 2000; Liu et al., 2008; Brocato and Hooper, 2019). The clinical types were categorized into four groups (mild, moderate, severe, and critical) according to the severity of hantavirus infection (Table 1). To understand the relationship between serum ferritin, PCT, CRP, and hantavirus infection more clearly, we divided the patients into two groups (mild group: mild and moderate type patients, and severe group: severe and critical type patients).
TABLE 1
| Clinical types | Manifestations* |
| Mild | T < 39°C; mild toxemic symptoms and renal damage; no bleeding except for hemorrhagic spots, no shock and oliguria |
| Medium | T = 39°C∼40°C; severe toxemic symptoms and obvious chemosis; The systolic Bp < 90 mmHg, or pulse pressure < 26 mmHg during the whole clinical course; Obvious hemorrhage and oliguria, urinary protein “+++” |
| Severe | T > 40°C; severe toxemic symptoms and effusion, some may have toxemic psychiatric symptoms; Shock; Severe ecchymoses on skin and cavity hemorrhage; Oliguria lasting for <5 days or anuresis less than 2 days |
| Critical | Combining one of the following on severe style: Refractory shock; Hemorrhage of important organs; Oliguria lasting for >5 days, or anuresis for >2 days or urea nitrogen >120 mg/dl (42.84 mmol/L); Heart failure or pulmonary edema; Central nervous system damage such as cerebral edema, brain hemorrhage and cerebral hernia; Severe secondary infections |
Standard for the classification of HFRS severity.
*T, body temperature; BP, blood pressure.
Clinical Diagnosis and Data Collection
The clinical information of HFRS included the patients’ age, sex, admission days after fever, days in the hospital, primary disease or comorbidity, complication caused by HFRS, such as hemorrhage, bacterial co-infection, acute respiratory distress syndrome (ARDS), and multiple-organ dysfunction syndrome (MODS). Clinical symptoms, including hemoptysis, hematemesis, melena, hematuria, ecchymosis, and rupture or bleeding of internal organs of the body, were diagnosed with hemorrhage. The bacterial co-infection, including Staphylococcus aureus, methicillin-resistant S. aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Enterobacter aerogenes, was confirmed by liquid culture assay (blood, urine, or feces) combined with higher levels of CRP, PCT, and/or radiological evidence. ARDS and MODS were diagnosed according to the criteria (Ramirez, 2013; Fan E. et al., 2018).
Serum ferritin, PCT, and CRP were detected at least three times at the same timepoint (hospital admission, the third day in hospital, and the day patients were discharged or bacterial co-infection was detected) from the first day of admission to the last day. Other laboratory results, such as white blood cell (WBC), platelet (PLT), alanine transaminase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and α-hydroxybutyrate dehydrogenase (α-HBDH), were detected at least once at a different stage of HFRS. All the patients with HFRS received ribavirin and supportive treatment (maintaining fluid and electrolyte balance).
Statistical Analysis
Statistical analysis was performed using SAS 9.3 software. Categorical data were presented as numbers and percentages, and analyzed using Pearson’s Chi-square test or Fisher’s Exact. Distributed data were described using mean and standard deviation and analyzed using Student’s t-test. Non-parametric data were analyzed using the Mann–Whitney U test, shown as median and interquartile range (IQR). Results with a value of p < 0.05 were deemed as statistically significant. To make data conform to normality and reduce the variability, we used log transformation, especially in data sets that included outlying observations. Predictive values of variables for disease severity, bacterial co-infection, or prognosis were tested with receiver operating characteristic (ROC) curves and quantified by calculating the area under the ROC curve (AUC) and the 95% confidence interval (CI) using SPSS 19.0 software (SPSS Inc., Chicago, IL, United States; Fan X. et al., 2018).
Results
Clinical Information
The study included 373 patients with HFRS (286 men and 87 women) with a mean age of 45.38 ± 14.13 years; 108 patients were grouped into severe types (97 critical forms and 11 severe forms) and 265 patients were grouped into mild types (47 mild forms and 218 medium forms). Non-bacterial co-infections included 258 patients, while bacterial co-infections included 115 patients. Survivors included 359 patients and 14 died of HFRS. Patients who died of HFRS were all in the severe group (p < 0.001). The patients in the severe group had higher frequencies of complication of hemorrhage (p < 0.001), hepatic injury (ALT > 50 U/L and AST > 40 U/L) (p < 0.001), ARDS (p < 0.001), MODS (p < 0.001) than those of the mild group. Continuous renal replacement therapy (CRRT) and respirators were used in the severe group (p < 0.001). The patients in the severe group had a longer hospital stay than those in the mild group (p < 0.001), but there was no significant difference in incubation between the two groups. Higher WBC and lower PLT in the severe group were other characteristics (p = 0.147 and p < 0.001, respectively). The patients in the severe group had more severe hepatic and myocardial injury than those in the mild group.
Serum Ferritin, Procalcitonin, and C-Reactive Protein Association With Severity of Virus Infection
In the 373 patients with HFRS, the median serum ferritin level was 3620.3 ng/ml, ranging from 70.1 to 117,500 ng/ml. The median serum ferritin level in the severe group was higher than that of the mild group (p < 0.001, Table 2). The median PCT and CRP levels in these patients with HFRS were 1.84 (0.02–82.92) ng/ml and 32 (1.25–212) mg/l, respectively, which were higher than the reference value of less than 0.5 ng/ml and 10 mg/l; both PCT and CRP in the severe group were higher than those of the mild group (p < 0.001; Table 2).
TABLE 2
| Variables | Mild (n = 265) | Severe (n = 108) | P-value |
| Male, n (%) | 208 (78.5) | 78 (72.2) | 0.1975 |
| Age, years | 45 (32–54) | 49.3 ± 12.6 | 0.0009 |
| Time from symptom onset to hospital admission, days | 5 (4–7) | 5 (4–6) | 0.0353 |
| Hospital stay, days | 7 (5–9) | 9 (7–13) | <0.0001 |
| Comorbidity | |||
| Hypertension, n (%) | 10 (3.8) | 11 (10.2) | 0.0148 |
| Coronary heart disease, n (%) | 2 (0.8) | 2 (1.9) | 0.7048 |
| Diabetes, n (%) | 8 (3.0) | 10 (9.3) | 0.0108 |
| Complication | |||
| Hemorrhage, n (%) | 34 (12.8) | 71 (65.7) | <0.0001 |
| Hepatic injury, n (%) | 169 (63.8) | 90 (83.3) | 0.0002 |
| Myocardial damage, n (%) | 80 (30.2) | 76 (70.4) | <0.0001 |
| Bacterial infection, n (%) | 78 (29.4) | 37 (34.3) | 0.3600 |
| ARDS, n (%) | 0 | 19 (17.6) | <0.0001 |
| MODS, n (%) | 0 | 21 (19.4) | <0.0001 |
| Respiratory support, n (%) | 0 | 35 (32.4) | <0.0001 |
| CRRT, n (%) | 0 | 42 (38.9) | <0.0001 |
| Number of death, n (%) | 0 | 14 (13.0) | <0.0001 |
| Parameters | |||
| WBC, × 109/L | 8.4 (5.3–10.8) | 9.6 (5.5–11.5) | 0.1407 |
| PLT, × 109/L | 109.0 (88.0–125.0) | 39.0 (20.0–85.0) | <0.0001 |
| AST, U/L | 88.8 (56.0–155.6) | 149.4 (77.5–297.4) | <0.0001 |
| ALT, U/L | 109.1 (68.9–187.0) | 88.0 (67.9–173.2) | 0.2602 |
| LDH, U/L | 415.0 (344.0–536.0) | 655.0 (415.0–1011.0) | <0.0001 |
| α-HBDH, U/L | 303.0 (247.0–376.5) | 515.0 (340.0–804.0) | <0.0001 |
| PCT, ng/ml | 1.3 (0.8–2.1) | 3.8 (2.4–6.8) | <0.0001 |
| Ferritin, ng/ml | 2502.4 (1237.7–6670.5) | 9930.5 (3604.3–17080.0) | <0.0001 |
| CRP, mg/l | 29.5 (16.4–53.2) | 42.1 (25.8–69.4) | 0.0006 |
| Lg PCT | 0.1 (−0.1 to 0.3) | 0.6 (0.4–0.8) | <0.0001 |
| Lg Ferritin | 3.4 (3.1–3.8) | 4.0 (3.6–4.2) | <0.0001 |
| Lg CRP | 1.5 ± 0.4 | 1.6 (1.4–1.8) | 0.0006 |
Demographics and clinical and laboratory data at admission in the patients with HFRS of different clinical types*.
*ARDS, acute respiratory distress syndrome; MODS, multiple organ dysfunction syndrome; CRRT, continuous renal replacement therapy; WBC, white blood cell count; PLT, platelet; ALT, alanine transaminase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; and α-HBDH, α-hydroxybutyrate dehydrogenase; Lg Ferritin, Lg PCT, and Lg CRP, Ferritin, procalcitonin, and CRP after log10 transformation.
In 258 patients without bacterial co-infection (73 patients in the severe group and 185 patients in the mild group), the median serum ferritin level of the severe group [976 ng/ml (range 219–3,683.3 ng/ml)] was higher than that of mild [778.4 ng/ml (range 70.1–5,310 ng/ml)]. The median PCT level of the severe group [1.26 ng/ml (range 0.02–12.93 ng/ml)] was higher than that of the mild group [0.99 ng/ml (range 0.08–41.3 ng/ml)]. The median CRP level of the severe group [32.5 mg/l (range 3.11–509.9 mg/l)] was higher than that of the mild group [24.9 mg/l (range 1.25–167 mg/l)], although the difference was not statistically significant.
In the 21 patients with MODS (all in the severe group), the median levels of serum ferritin, PCT, and CRP were 33,070 ng/ml (range 20,691–99,800 ng/ml), 4.13 ng/ml (range 0.26–56 ng/ml), and 49.4 mg/l (range 8.78–127 mg/l), respectively; in the 19 patients with ARDS (all in the severe group), the median levels of serum ferritin, PCT, and CRP were 18,511 ng/ml (range 10,550–99,800 ng/ml), 5.0 ng/ml (range 0.02–82.92 ng/ml), and 55.89 mg/l (range 5.02–145 mg/l), respectively.
The AUC value of serum ferritin for predicting the severity of HFRS was 0.732 (95% CI 0.678–0.786, p < 0.001), while PCT and CRP for predicting the severity of HFRS were 0.824 (95% CI 0.773–0.875, p < 0.001) and 0.614 (95% CI 0.552–0.676, p = 0.001), respectively (Figure 1 and Table 3), showing that PCT and ferritin may be potential biomarkers to predict the severity of HFRS.
FIGURE 1
TABLE 3
| Variables | AUC | p value | Cut-off value | Sensitivity | Specificity | 95% CI for AUC | |
| Lower | Upper | ||||||
| Lg PCT | 0.824 | <0.001 | 0.45 | 0.75 | 0.88 | 0.773 | 0.875 |
| Lg CRP | 0.614 | 0.001 | 1.41 | 0.76 | 0.45 | 0.552 | 0.676 |
| Lg Ferritin | 0.732 | <0.001 | 3.55 | 0.76 | 0.60 | 0.678 | 0.786 |
Predictive values of parameters for the severity of HFRS*.
*AUC, area under the receiver operating characteristic curve; CI, confidence interval; Lg PCT, procalcitonin after log10 transformation; Lg CRP, C-reactive protein after log10 transformation; Lg Ferritin, serum ferritin after log10 transformation.
Serum Ferritin, Procalcitonin, and C-Reactive Protein Association With Bacterial Co-infection
In 373 patients with HFRS, 115 patients combined bacterial co-infection (37 patients in severe group and 78 patients in mild group). The incidence of secondary bacterial co-infection of patients in the hospital was 30.8%, generally occurring on days 7–10 of the virus infection. The level of serum ferritin in patients with bacterial co-infection was significantly higher than that in patients with non-bacterial co-infection. The median serum ferritin level in 115 patients with bacterial co-infection [2,799.0 ng/ml (range 1,542.8–5,941.7 ng/ml)] was higher than that in 258 patients with non-bacterial co-infection [807.85 ng/ml (range 515.1–1,358.8 ng/ml)] (p < 0.001, Table 3). The AUC value of serum ferritin for predicting bacterial co-infection was 0.54 (95% CI 0.477–0.602, p = 0.214).
Procalcitonin and CRP in patients with bacterial co-infection were significantly higher than those in patients with non-bacterial co-infection (both p < 0.001, Table 4). The median PCT and CRP levels in 115 patients with bacterial co-infection [2.09 ng/ml (range 0.99–3.6 ng/ml) and 43.2 mg/l (range 20.5–75.3 mg/l)] were higher than those in 258 patients with non-bacterial co-infections [0.99 ng/ml (range 0.63–2.00 ng/ml) and 26.4 mg/l (range 14.2–46.3 mg/l), respectively, both p < 0.001] (Table 4). The AUC values of PCT and CRP for predicting bacterial co-infection were 0.527 (95% CI 0.464–0.589, p = 0.401) and 0.588 (95% CI 0.525–0.652, p = 0.005), respectively (Figure 2 and Table 5). These results showed that CRP can be used as a potential biomarker to predict bacterial co-infection in patients with HFRS.
TABLE 4
| Variables | Non-bacterial infection (n = 258) | Bacterial infection (n = 115) | P-value |
| Male, n (%) | 199 (77.7) | 87 (75.7) | 0.7550 |
| Age, years | 46 (34–54) | 48.1 ± 14.3 | 0.0143 |
| Time from symptom onset to hospital admission, days | 5 (4–7) | 5 (4–7) | 0.3315 |
| Hospital stays, days | 7 (5–9) | 9 (6–12) | <0.0001 |
| Comorbidity | |||
| Hypertension, n (%) | 9 (3.5) | 12 (10.4) | 0.0072 |
| Coronary heart disease, n (%) | 1 (0.4) | 3 (2.6) | 0.1679 |
| Diabetes, n (%) | 5 (1.9) | 13 (11.3) | <0.0001 |
| Complication | |||
| Hemorrhage, n (%) | 18 (7.0) | 87 (75.7) | <0.0001 |
| Hepatic injury, n (%) | 171 (66.3) | 88 (76.5) | 0.0752 |
| Myocardial damage, n (%) | 104 (40.3) | 52 (45.2) | 0.4228 |
| CNS damage | 0 | 1 (0.9) | 0.3351 |
| ARDS, n (%) | 2 (0.78) | 17 (14.8) | <0.0001 |
| MODS, n (%) | 0 | 21 (18.3) | <0.0001 |
| Respiratory support, n (%) | 2 (0.8) | 33 (28.7) | <0.0001 |
| CRRT, n (%) | 20 (7.8) | 22 (19.1) | 0.0013 |
| Number of death, n (%) | 0 | 14 (12.2) | <0.0001 |
| Parameters | |||
| WBC, × 109/L | 8.9 (5.5–10.8) | 8.3 (4.9–11.2) | 0.9748 |
| PLT, × 109/L | 98.0 (54.0–121.0) | 94.5 (50.0–120.0) | 0.4762 |
| AST, U/L | 98.4 (58.6–183.9) | 128.4 (72.1–212.6) | 0.0273 |
| ALT, U/L | 104.6 (64.0–184.0) | 108.0 (74.0–168.0) | 0.5610 |
| LDH, U/L | 460 (345–657) | 489.0 (380.0–765.5) | 0.1093 |
| α-HBDH, U/L | 333.0 (259.0–496.0) | 364.0 (289.0–556.0) | 0.0295 |
| PCT, ng/ml | 0.99 (0.63–2.00) | 2.09 (0.99–3.6) | 0.0001 |
| Ferritin, ng/ml | 807.85 (515.1–1358.8) | 2799.0 (1542.8–5941.7) | 0.0001 |
| CRP, mg/l | 26.4 (14.2–46.3) | 43.2 (20.5–75.3) | 0.0001 |
| Lg PCT | −0.004 (−0.2 to 0.3) | 0.3 (−0.004 to 0.6) | 0.0001 |
| Lg Ferritin | 2.9 ± 0.3 | 3.4 ± 0.4 | 0.0001 |
| Lg CRP | 1.4 ± 0.4 | 1.6 (1.3–1.9) | 0.0001 |
Demographics and clinical and laboratory data at admission in the patients with and without bacterial infection*.
*ARDS, acute respiratory distress syndrome; MODS, multiple organ dysfunction syndrome; CNS, central nervous system; CRRT, continuous renal replacement therapy; WBC, white blood cell count; PLT, platelet; ALT, alanine transaminase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; and α-HBDH, α-hydroxybutyrate dehydrogenase; Lg Ferritin, Lg PCT, and Lg CRP, Ferritin, procalcitonin, and CRP after log10 transformation.
FIGURE 2
TABLE 5
| Variables | AUC | p value | Cut-off value | Sensitivity | Specificity | 95% CI for AUC | |
| Lower | Upper | ||||||
| Lg PCT | 0.527 | 0.401 | 0.16 | 0.66 | 0.44 | 0.464 | 0.589 |
| Lg CRP | 0.588 | 0.005 | 1.73 | 0.43 | 0.76 | 0.525 | 0.652 |
| Lg Ferritin | 0.540 | 0.214 | 3.32 | 0.758 | 0.333 | 0.477 | 0.602 |
Predictive values of parameters for the bacterial infection of HFRS*.
*AUC, area under the receiver operating characteristic (ROC) curve; CI, confidence interval; Lg PCT, procalcitonin after log10 transformation; Lg CRP, C-reactive protein after log10 transformation; Lg Ferritin, serum ferritin after log10 transformation.
Serum Ferritin, Procalcitonin, and C-Reactive Protein Association With Patient Survival
Of the 373 patients, 14 patients died of HFRS with a mortality rate of 3.8%. All the non-survivors had a severe hemorrhage, hepatic injury, myocardial damage, and even MODS, and received CRRT treatment and/or respiratory support. The occurrence of ARDS and MODS in non-survivors was significantly higher than those of survivors (both p < 0.001, Table 6). Non-survivors had a significantly lower PLT, but higher LDH and α-HBDH (p < 0.001, Table 6).
TABLE 6
| Variables | Survivors (n = 359) | Non-survivors (n = 14) | P-value |
| Male, n (%) | 273 (76.0) | 13 (92.9) | 0.1445 |
| Age, years | 46 (35–56) | 49 (43–55) | 0.5351 |
| Time from symptom onset to hospital admission, days | 5 (4–7) | 5 (4–7) | 0.887 |
| Hospital stays, days | 7 (5–10) | 13.7 ± 9.0 | 0.0066 |
| Comorbidity | |||
| Hypertension, n (%) | 17 (4.7) | 4 (28.6) | 0.0047 |
| Coronary heart disease, n (%) | 1 (0.3) | 3 (21.4) | <0.0001 |
| Diabetes, n (%) | 16 (4.5) | 2 (14.3) | 0.1173 |
| Complication | |||
| Hemorrhage, n (%) | 91 (25.3) | 14 (100.0) | <0.0001 |
| Hepatic injury, n (%) | 245 (68.2) | 14 (100.0) | 0.0114 |
| Myocardial damage, n (%) | 142 (39.6) | 14 (100.0) | <0.0001 |
| ARDS, n (%) | 7 (1.9) | 12 (85.7) | <0.0001 |
| MODS, n (%) | 7 (1.9) | 14 (100.0) | <0.0001 |
| Respiratory support, n (%) | 27 (0.75) | 8 (57.1) | <0.0001 |
| CRRT, n (%) | 28 (0.78) | 14 (100.0) | <0.0001 |
| Parameters | |||
| WBC, × 109/L | 8.9 (5.3–11.0) | 8.3 (4.9–10.3) | 0.6899 |
| PLT, × 109/L | 102 (65–121) | 29 (10–60) | 0.0001 |
| AST, U/L | 101.0 (67.9–182.5) | 145.2 (72.7–275.0) | 0.1812 |
| ALT, U/L | 99.7 (60.0–183.9) | 172.0 (86.0–306.1) | 0.0458 |
| LDH, U/L | 443.0 (348.0–623.0) | 1343.1 ± 883.4 | <0.0001 |
| α-HBDH, U/L | 328.0 (263.0–461.0) | 698.0 (377.0–1114.0) | 0.0001 |
| PCT, ng/ml | 1.7 (0.9–3.1) | 3.6 (2.2–42.9) | 0.0009 |
| Ferritin, ng/ml | 3410.0 (1456.9–9028.0) | 21708.0 (14101.0–36078.0) | <0.0001 |
| CRP, mg/l | 31.2 (17.6–60.1) | 65.0 ± 35.5 | 0.0055 |
| Lg PCT | 0.2 (−0.6 to 0.5) | 0.8 ± 0.8 | 0.0009 |
| Lg Ferritin | 3.6 ± 0.6 | 4.3 ± 0.4 | <0.0001 |
| Lg CRP | 1.5 (1.3–1.8) | 1.7 ± 0.3 | 0.0054 |
Demographics and clinical and laboratory data at admission in survivors and non-survivors of patients with HFRS*.
*ARDS, acute respiratory distress syndrome; MODS, multiple organ dysfunction syndrome; CRRT, continuous renal replacement therapy; WBC, white blood cell count; PLT, platelet; ALT, alanine transaminase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; and α-HBDH, α-hydroxybutyrate dehydrogenase; Lg Ferritin, Lg PCT, and Lg CRP, Ferritin, procalcitonin, and CRP after log10 transformation.
The levels of serum ferritin, PCT, and CRP in non-survivors were significantly higher compared with survivors (all p < 0.001, Table 6). The median serum ferritin level of non-survivors [21,708.0 ng/ml (range 14,101.0–36,078.0 ng/ml)] was higher than that in 359 survivors [3,410.0 ng/ml (range 1,456.9–9,028.0 ng/ml)] (p < 0.001, Table 6). The median PCT [3.6 ng/ml (range 2.2–42.9 ng/ml)] and CRP [50.4 mg/l (range 29.5–100.5 mg/l)] levels of non-survivors was higher than those in 359 survivors [1.7 ng/ml (range 0.9–3.1 ng/ml) and 31.2 mg/l (range 17.6–60.1 mg/l)], respectively (p < 0.001, Table 6).
The AUC values of serum ferritin, PCT, and CRP for predicting mortality were 0.853 (95% CI 0.774–0.933, p < 0.001), 0.737 (95% CI 0.587–0.887, p = 0.002), and 0.703 (95% CI 0.577–0.828, p = 0.008), respectively (Figure 3 and Table 7), showing that serum ferritin was the best marker to predict mortality of HFRS.
FIGURE 3
TABLE 7
| Variables | AUC | p value | Cut-off value | Sensitivity | Specificity | 95% CI for AUC | |
| Lower | Upper | ||||||
| Lg PCT | 0.737 | 0.002 | 0.50 | 0.733 | 0.715 | 0.587 | 0.887 |
| Lg CRP | 0.703 | 0.008 | 1.62 | 0.867 | 0.601 | 0.577 | 0.828 |
| Lg Ferritin | 0.853 | <0.001 | 4.03 | 0.933 | 0.739 | 0.774 | 0.933 |
Predictive values of parameters for the mortality of HFRS*.
*AUC, area under the receiver operating characteristic (ROC) curve; CI, confidence interval; Lg PCT, procalcitonin after log10 transformation; Lg CRP, C-reactive protein after log10 transformation; Lg Ferritin, serum ferritin after log10 transformation.
Discussion
This study analyzed the changes of serum ferritin, PCT, and CRP in patients with HFRS and compared their clinical significance for the prediction of severity and mortality in patients with HFRS. Results showed that serum ferritin and PCT concentrations have a robust association with severity and mortality of HFRS, which can be used as promising predictors of severity and mortality, and CRP may be an effective biomarker to assess bacterial co-infection in HFRS.
High levels of serum ferritin have been detected in patients of acute viral infections, such as Epstein-Barr virus, human immunodeficiency virus, and dengue virus, and it is associated with the severity and poor prognosis of virus infection (Riera et al., 1994; Mustafa et al., 2001; van de Veerdonk et al., 2012; Soundravally et al., 2015). Serum ferritin is associated with viremia and is significantly elevated in patients with hemorrhagic manifestation and the fatal outcome of the Ebola virus (McElroy et al., 2014; van der Ven et al., 2015). Recent studies have shown that serum ferritin is also a prognostic biomarker that contributes to therapeutic decision-making concerning patients with COVID-19 (Cooper et al., 2020; Kappert et al., 2020). Our results have demonstrated that serum ferritin is a potential biomarker to predict the severity of patients with HFRS, with the cutoff value of 3,548 ng/ml in serum concentration.
Procalcitonin and CRP are considered the most sensitive and effective biomarkers to assess the severity of bacterial co-infection or sepsis (Hu et al., 2017; Cui et al., 2019). Recently, PCT has been reported to be associated with the severity and prognosis of the hantavirus infection (Fan X. et al., 2018) and COVID-19 (Guan et al., 2020; Huang et al., 2020; Lu et al., 2020; Zhang et al., 2020). In the present study, we compared the clinical significance of serum ferritin, PCT, and CRP in patients with HFRS, and found that they were all associated with mortality, but the serum ferritin had better performance than both PCT and CRP to predict the prognosis of HFRS.
Procalcitonin is also shown to be associated with the severity and prognosis of HFRS, as PCT greater than 2.8 ng/ml suggested a severe virus infection and more than 3.16 ng/ml indicated a very poor prognosis. In patients with HFRS with bacterial co-infection, PCT began to rise in the viremia stage, so PCT is unable to distinguish between viral and bacterial co-infections. In contrast, the level of CRP was normally or slightly elevated in hantavirus infection, but it was significantly increased in patients with HFRS with bacterial co-infection, which was related to the severity of infection and prognosis. Therefore, it can be used in the evaluation of bacterial co-infection and prognosis in patients with HFRS.
Conclusion
The study showed that serum ferritin and PCT have a robust association with the severity and mortality of HFRS, which can be used as a promising predictor of severity and mortality in rodent-borne disease. CRP may be an effective biomarker to assess bacterial co-infection in HFRS.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.
Ethics statement
The studies involving human participants were reviewed and approved by the Ethics Committee of The First Hospital of Jilin University. The patients/participants provided their written informed consent to participate in this study.
Author contributions
LC and QL conceived the project. LC planned the study. ND, LL, YZ, and KZ collected the data. LC, ZW, and QL analyzed the data and drafted the manuscript. All authors were involved in critically revising the manuscript and approving the final version.
Funding
This study was supported by the Science and Technology Innovation Project in Foshan, Guangdong Province, China (2020001000151).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
BarutS.DincerF.SahinI.OzyurtH.AkkusM.ErkorkmazU. (2010). Increased serum ferritin levels in patients with Crimean-Congo hemorrhagic fever: can it be a new severity criterion?Int. J. Infect. Dis.14e50–e54. 10.1016/j.ijid.2009.03.009
2
BrocatoR. L.HooperJ. W. (2019). Progress on the prevention and treatment of Hantavirus disease.Viruses11:610. 10.3390/v11070610
3
CooperI. D.CroftsC. A. P.DiNicolantonioJ. J.MalhotraA.ElliottB.KyriakidouY.et al (2020). Relationships between hyperinsulinaemia, magnesium, vitamin D, thrombosis and COVID-19: rationale for clinical management.Open Heart7:e001356. 10.1136/openhrt-2020-001356
4
CuiN.ZhangH.ChenZ.YuZ. (2019). Prognostic significance of PCT and CRP evaluation for adult ICU patients with sepsis and septic shock: retrospective analysis of 59 cases.J. Int. Med. Res.471573–1579. 10.1177/0300060518822404
5
DuH.WangP. Z.LiJ.BaiL.LiH.YuH. T.et al (2014). Clinical characteristics and outcomes in critical patients with hemorrhagic fever with renal syndrome.BMC Infect. Dis.14:191. 10.1186/1471-2334-14-191
6
EscutenaireS.PastoretP. P. (2000). Hantavirus infections.Rev. Sci. Tech.1964–78. 10.20506/rst.19.1.1209
7
FanE.BrodieD.SlutskyA. S. (2018). Acute respiratory distress syndrome: advances in diagnosis and treatment.JAMA319698–710. 10.1001/jama.2017.21907
8
FanX.DengH.SangJ.LiN.ZhangX.HanQ.et al (2018). High serum procalcitonin concentrations in patients with hemorrhagic fever with renal syndrome caused by Hantaan virus.Front. Cell. Infect. Microbiol.8:129. 10.3389/fcimb.2018.00129
9
Franco-MartinezL.CeronJ. J.Vicente-RomeroM. R.BernalE.Torres CanteroA.TeclesF.et al (2021). Salivary ferritin changes in patients with COVID-19.Int. J. Environ. Res. Public. Health.19:41. 10.3390/ijerph19010041
10
GuanW. J.NiZ. Y.HuY.LiangW. H.OuC. Q.HeJ. X.et al (2020). Clinical characteristics of Coronavirus disease 2019 in China.N. Engl. J. Med.3821708–1720. 10.1056/nejmoa2002032
11
HuL.ShiQ.ShiM.LiuR.WangC. (2017). Diagnostic value of PCT and CRP for detecting serious bacterial co-infections in patients with fever of unknown origin: a systematic review and meta-analysis.Immunohistochem. Mol. Morphol.25e61–e69. 10.1097/PAI.0000000000000552
12
HuangC.WangY.LiX.RenL.ZhaoJ.HuY.et al (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet395497–506. 10.1016/S0140-6736(20)30183-5
13
JonssonC. B.FigueiredoL. T.VapalahtiO. (2010). A global perspective on hantavirus ecology, epidemiology, and disease.Clin. Microbiol. Rev.23412–441. 10.1128/CMR.00062-09
14
KappertK.JahicA.TauberR. (2020). Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases.Biomarkers.25616–625. 10.1080/1354750X.2020.1797880
15
KyriazopoulouE.LeventogiannisK.Norrby-TeglundA.DimopoulosG.PantaziA.OrfanosS. E.et al (2017). Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis.BMC Med.15:172. 10.1186/s12916-017-0930-5
16
LiuF.LiL.XuM.WuJ.LuoD.ZhuY.et al (2020). Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.J. Clin. Virol.127:104370. 10.1016/j.jcv.2020.104370
17
LiuZ.ZhaoQ.HanQ.GaoM.ZhangN. (2008). Serum thrombospondin-1 is altered in patients with hemorrhagic fever with renal syndrome.J. Med. Virol.801799–1803. 10.1002/jmv.21270
18
LuR.ZhaoX.LiJ.NiuP.YangB.WuH.et al (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.Lancet.395565–574. 10.1016/S0140-6736(20)30251-8
19
McElroyA. K.EricksonB. R.FlietstraT. D.RollinP. E.NicholS. T.TownerJ. S.et al (2014). Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome.J. Infect. Dis.210558–566. 10.1093/infdis/jiu088
20
MustafaA. S.ElbishbishiE. A.AgarwalR.ChaturvediU. C. (2001). Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever.FEMS Immunol. Med. Microbiol.30229–233. 10.1111/j.1574-695X.2001.tb01575.x
21
PanF.YangL.LiY.LiangB.LiL.YeT.et al (2020). Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study.Int. J. Med. Sci.171281–1292. 10.7150/ijms.46614
22
RamirezM. (2013). Multiple organ dysfunction syndrome.Curr. Probl. Pediatr. Adolesc. Health Care43273–277. 10.1016/j.cppeds.2013.10.003
23
RieraA.GimferrerE.CadafalchJ.RemachaA.MartinS. (1994). Prevalence of high serum and red cell ferritin levels in HIV-infected patients.Haematologica.79165–167.
24
ShinJ. H.YuE.KimE. N.KimC. J. (2018). C-reactive protein overexpression in the background liver of hepatitis B virus-associated hepatocellular carcinoma is a prognostic biomarker.J. Pathol. Transl. Med.52267–274. 10.4132/jptm.2018.07.14
25
SoundravallyR.AgieshkumarB.DaisyM.SherinJ.CleetusC. C. (2015). Ferritin levels predict severe dengue.Infection.4313–19. 10.1007/s15010-014-0683-4
26
TjendraY.Al ManaA. F.EspejoA. P.AkgunY.MillanN. C.Gomez-FernandezC.et al (2020). Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers.Arch. Pathol. Lab. Med.1441465–1474. 10.5858/arpa.2020-0471-SA
27
ValeroN.MosqueraJ.TorresM.DuranA.VelasteguiM.ReyesJ.et al (2019). Increased serum ferritin and interleukin-18 levels in children with dengue.Braz. J. Microbiol.50649–656. 10.1007/s42770-019-00105-2
28
van de VeerdonkF. L.WeverP. C.HermansM. H.FijnheerR.JoostenL. A.van der MeerJ. W.et al (2012). IL-18 serum concentration is markedly elevated in acute EBV infection and can serve as a marker for disease severity.J. Infect. Dis.206197–201. 10.1093/infdis/jis335
29
van der VenA. J.NeteaM. G.van der MeerJ. W.de MastQ. (2015). Ebola virus disease has features of hemophagocytic lymphohistiocytosis syndrome.Front. Med.2:4. 10.3389/fmed.2015.00004
30
WangP. Z.LiZ. D.YuH. T.ZhangY.WangW.JiangW.et al (2012). Elevated serum concentrations of inflammatory cytokines and chemokines in patients with haemorrhagic fever with renal syndrome.J. Int. Med. Res.40648–656. 10.1177/147323001204000227
31
ZhangJ. J.CaoY. Y.TanG.DongX.WangB. C.LinJ.et al (2021). Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients.Allergy.76533–550. 10.1111/all.14496
32
ZhangJ. J.DongX.CaoY. Y.YuanY. D.YangY. B.YanY. Q.et al (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.Allergy751730–1741. 10.1111/all.14238
33
ZhangY.MaY.ZhangC.ZhangY.ZhuangR.LiuB.et al (2015). Soluble scavenger receptor CD163 is associated with severe acute kidney injury in patients with Hantaan virus infection.Viral. Immunol.28241–246. 10.1089/vim.2014.0112
34
ZhangY. Z.ZouY.FuZ. F.PlyusninA. (2010). Hantavirus infections in humans and animals, China.Emerg. Infect. Dis.161195–1203. 10.3201/eid1608.090470
35
ZhouJ.ZhouJ.WuZ. Q.GoyalH.XuH. G. (2021). Ferritin index is a strong prognostic marker in adult hemophagocytic lymphohistiocytosis.Int. J. Clin. Pract.75:e13704. 10.1111/ijcp.13704
36
ZhouY. Z.TengX. B.HanM. F.ShiJ. F.LiC. X.ZhangX. H.et al (2021). The value of PCT, IL-6, and CRP in the early diagnosis and evaluation of COVID-19.Eur. Rev. Med. Pharmacol. Sci.251097–1100. 10.26355/eurrev_202101_24680
Summary
Keywords
hantaviruses, serum ferritin, hemorrhagic fever with renal syndrome, C-reactive protein, procalcitonin
Citation
Che L, Wang Z, Du N, Li L, Zhao Y, Zhang K and Liu Q (2022) Evaluation of Serum Ferritin, Procalcitonin, and C-Reactive Protein for the Prediction of Severity and Mortality in Hemorrhagic Fever With Renal Syndrome. Front. Microbiol. 13:865233. doi: 10.3389/fmicb.2022.865233
Received
29 January 2022
Accepted
08 March 2022
Published
23 May 2022
Volume
13 - 2022
Edited by
Svetlana Khaiboullina, University of Nevada, Reno, United States
Reviewed by
Silvia Spoto, Policlinico Universitario Campus Bio-Medico, Italy; Evdoxia Kyriazopoulou, National and Kapodistrian University of Athens, Greece
Updates
Copyright
© 2022 Che, Wang, Du, Li, Zhao, Zhang and Liu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Quan Liu, liuquan1973@hotmail.com
This article was submitted to Infectious Agents and Disease, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.